Here we demonstrate that a CXCR2 antagonist, AZD5069, as a single agent, was beneficial in the prevention of progression of insulin resistance and liver pathology reminiscent of NASH/NAFLD. The gene discussed is CXCR2; the disease is metabolic dysfunction-associated steatotic liver disease.